Cardurion Pharmaceuticals, Inc.
Cardurion is a next-generation cardiovascular company dedicated to addressing unmet needs in heart disease through innovative therapeutics. Founded by physician-scientists, it focuses on groundbreaking clinical programs targeting heart failure and other cardiovascular diseases, leveraging world-class expertise in cardiovascular signaling pathways to develop novel treatments and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Cardurion Pharmaceuticals, Inc.
78 Blanchard Road, Suite 200, Burlington, MA 01803, USA
Patents
Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-12006319-B2
View DetailsProcess for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11999741-B2
View DetailsSubstituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
US-11795172-B2
View DetailsProcess for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11370795-B2
View Details
Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-12006319-B2
View DetailsProcess for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11999741-B2
View DetailsSubstituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
US-11795172-B2
View DetailsProcess for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US-11370795-B2
View DetailsProducts
PDE9 Inhibitor
A treatment under development for both types of chronic heart failure, HFrEF and HFpEF, aiming to improve efficacy when added to existing medical therapies.
CaMKII Inhibitor
A drug in clinical trials targeting hyperactivated CaMKII, intended to treat various cardiovascular diseases including CPVT, heart failure, and atrial fibrillation.
Clinical Trials
Research studies designed to evaluate the safety and efficacy of Cardurion's investigational medicines for cardiovascular diseases.
Medicinal Chemistry and Molecular Biology Services
Specialized services in medicinal chemistry, computational molecular modeling, and genetic engineering to support cardiovascular research.
PDE9 Inhibitor
A treatment under development for both types of chronic heart failure, HFrEF and HFpEF, aiming to improve efficacy when added to existing medical therapies.
CaMKII Inhibitor
A drug in clinical trials targeting hyperactivated CaMKII, intended to treat various cardiovascular diseases including CPVT, heart failure, and atrial fibrillation.
Clinical Trials
Research studies designed to evaluate the safety and efficacy of Cardurion's investigational medicines for cardiovascular diseases.
Medicinal Chemistry and Molecular Biology Services
Specialized services in medicinal chemistry, computational molecular modeling, and genetic engineering to support cardiovascular research.
News & Updates
Cardurion announced a private investment of up to $300 million from Polaris Partners, supporting its growth and pipeline development in cardiovascular therapeutics.
Marcia Moore joins Cardurion with over 30 years of pharmaceutical and biotech leadership experience to support pipeline advancement.
The company has commenced dosing patients in a large-scale trial to evaluate CRD-740 for heart failure treatment.
FDA accepted the IND for CRD-733, and a Phase 1 trial has been initiated to evaluate safety and pharmacodynamics.
Cardurion announced a private investment of up to $300 million from Polaris Partners, supporting its growth and pipeline development in cardiovascular therapeutics.
Marcia Moore joins Cardurion with over 30 years of pharmaceutical and biotech leadership experience to support pipeline advancement.
The company has commenced dosing patients in a large-scale trial to evaluate CRD-740 for heart failure treatment.
FDA accepted the IND for CRD-733, and a Phase 1 trial has been initiated to evaluate safety and pharmacodynamics.